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Tourette syndrome (TS) is a disabling neuropsychiatric disorder characterised by persistent motor and vocal 
tics. TS is a highly comorbid state, hence, patients might experience anxiety, obsessions, compulsions, sleep 
abnormalities, depression, emotional liability, learning problems, and attention deficits in addition to tics. 
In spite of its complex heterogeneous genetic aetiology, recent studies highlighted a strong link between TS 
and genetic lesions in the HDC (L-histidine decarboxylase) gene, which encodes the enzyme that synthetises 
histamine, and the SLITRK1 (SLIT and TRK-like family member 1) gene, which encodes a transmembrane protein 
that was found to regulate neurite outgrowth. In addition to validating the contribution of a specific genetic 
aberration to the development of a particular pathology, animal models are crucial to dissect the function of 
disease-linked proteins, expose disease pathways through examination of genetic modifiers and discover as 
well as assess therapeutic strategies. Mice with a knockout of either Hdc or Slitrk1 exhibit anxiety and those 
lacking Hdc, display dopamine agonist-triggered stereotypic movements. However, the mouse knockouts do not 
spontaneously display tics, which are recognised as the hallmark of TS. In this review, we explore the features of 
the present genetic animal models of TS and identify reasons for their poor resemblance to the human condition. 
Importantly, we highlight ways forward aimed at developing a valuable genetic model of TS or a model that has 
good predictive validity in developing therapeutic drugs for the treatment of tics, hence potentially accelerating 
the arduous journey from lab to clinic.
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D1CT - D1 receptor cholera toxin;
HDC - L-histidine decarboxylase; 
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miRNA - microRNA; 
OCD - obsessive-compulsive disorder; 
SLITRK1 - SLIT and TRK-like family member 1; 
SMA - spinal muscular atrophy; 
SMN - survival of motor neurons; 
TS - Tourette syndrome; 
TTM - trichotillomania.
INTRODUCTION
Tourette syndrome (TS) is a developmental 
neuropsychiatric disorder whereby afflicted 
patients suffer from chronic fluctuating 
motor and vocal tics. In view of its complex 
heterogeneous genetic aetiology, for 
decades, the specific genes involved 
remained elusive. Breaking the mould, recent 
studies were successful in identifying genetic 
lesions in two genes: L-histidine decarboxylase 
(HDC), which encodes the rate limiting 
enzyme in histamine biosynthesis [1], and the 
SLIT and TRK-like family member 1 (SLITRK1), 
which encodes a transmembrane protein 
with strong homology to the axon guidance 
molecule, SLIT and the neurotrophin 
receptor, TRK [2]. These two emerging 
super candidates spurred the development 
of Slitrk1-knockout mice [3] and vigorous 
reanalysis of extensive data from previously-
generated Hdc-knockouts [4-6], with the 
aim of establishing a TS animal model. Both 
knockout mice are viable and although a 
shared characteristic is anxiety, which is a 
trait relevant to the features of TS, the models 
stop short of spontaneously displaying tics, 
that are recognised as the hallmark of TS. 
Mouse models are critical in the study of 
human disease, primarily because they allow 
us to validate the contribution of a specific 
chromosomal or genetic aberration to the 
disease phenotype. Secondarily, animal 
models open the door to the use of a variety 
of tools to dissect the function of disorder-
linked proteins, the uncovering of relevant 
disease pathways through the examination of 
genetic modifiers, and the discovery as well 
as the trialing of novel therapeutic strategies. 
In this review we probe the state of the art 
with regards to TS genetic models, identify 
the hurdles and go back to the drawing board 
to identify new approaches and strategies to 
hasten the arduous trip from lab to clinic.
CLINICAL SPECTRUM OF TS
TS has a male predominance and although the 
typical onset is around the age of five, it often 
remains under-diagnosed [7-9]. World-wide 
prevalence is estimated between 0.3 and 1% 
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[10,11]. Tics often peak in severity between age 
8 to 12 [12,13] and significantly decline after 
puberty in 80% of the cases [14]. Tics, which are 
sudden, repetitive motor and vocal behaviours 
involving discrete muscle groups, can be simple 
or complex. Simple motor tics are any sudden, 
meaningless movements that recur in bouts, 
such as eye blinking, rapid head jerks and 
shoulder shrugs. Although any part of the body 
can be affected, the face, head and shoulders 
are the most common areas involved. Complex 
motor tics seem more purposeful but they are 
still sudden movements, which involve more 
than one muscle group, such as facial grimaces, 
touching others, or pivoting movements. Vocal 
tics typically begin after the onset of motor 
tics and involve simple sudden utterance of 
sounds such as throat clearing, sniffing or 
coughing. More complex forms of vocal tics can 
be repetitive, purposeless utterance of words, 
phrases or statements that are out of context 
and expression of obscenities (coprolalia) 
[9,15]. The ability to suppress tics for brief 
intervals and, in most cases, the existence of 
premonitory sensory urges that are relieved 
by the execution of a tic, are features that 
differentiate TS from other movement disorders 
[15].
TS is a highly comorbid state, hence, in 
addition to tics, patients might experience 
anxiety, obsessions, compulsions, sleep 
abnormalities, depression, emotional liability, 
learning problems, and attention deficits, 
which precipitate distress [16-18]. In childhood, 
the most frequent comorbid disorder with 
TS is attention-deficit hyperactivity disorder 
(ADHD), which causes behaviour hyperactivity, 
impulsiveness and problems with attention 
focusing [19]. Obsessive-compulsive disorder 
(OCD) is also very frequent in TS, and usually 
causes more significant distress and functional 
impairment than the tics themselves [20]. 
The symptomatology of OCD is directed at 
reducing anxiety, is ritualized and changes little 
over time whereas tics are waxing and waning 
in course, are usually not dependent on anxiety, 
and involve fragmented movements. Both tics 
and obsessive-compulsive behaviours can be 
suppressed voluntarily and though worsened 
during periods of emotional excitement and 
fatigue, they plummet during periods that 
require focused attention and fine motor or 
vocal control [9,21,22]. Complex tics are usually 
difficult to distinguish from compulsions and 
in this context, TS and OCD are sometimes 
thought to be a common pathology with OCD 
being the mental form of TS and TS being 
the motor form of OCD [23]. Although these 
two disorders are diagnostically separate, 
aetiologically there is a common pattern 
including the involvement of similar brain 
areas in symptom manifestation [15,20,24]. If 
tics interfere with the daily life, antipsychotic 
agents, which reduce the symptoms but do not 
cure the disorder, are recommended [25,26]. 
In addition to pharmacological treatment, 
behavioural therapies and psychosocial 
interventions can also be effective [27].
TS GENE DISCOVERY: 
CONTAINED EXCITEMENT?
A significant genetic contribution to TS 
was identified through twin studies, where 
concordance rates over 50% were observed in 
monozygotic twins in contrast to rates below 
10% for dizygotic twins [28,29]. Furthermore, 
TS family studies show a greater rate of TS or 
chronic tics in first-degree relatives compared 
to rates in relatives of controls [30-33]. Initially 
thought to be a monogenic Mendelian disorder, 
TS is presently recognised as a complex 
disorder, with multiple genes interacting with 
various environmental factors to bring about 
the onset of symptoms. In this regard, several 
association studies assessing a variety of 
biologically plausible candidate genes as well 
as linkage screens were undertaken to underpin 
TS susceptibility loci [34-37]. Although the 
results fell short of remarkable considering the 
lack of independent reproducibility, the recent 
discovery of two causal genes with a role in 
TS, albeit minor, has generated considerable 
excitement in the field.
Focusing on a rare subset of patients with TS 
that have chromosomal anomalies, Abelson 
et al. [2] identified the SLITRK1 gene due to 
its proximity to a de novo chromosome 13 
inversion in a child with TS and ADHD but with 
no family history of either disorder or comorbid 
psychopathologies. Hypothesising that SLITRK1 
expression might be altered by a position 
effect, the authors genotyped 174 unrelated 
probands for lesions within the SLITRK1 gene. 
A frameshift mutation in the coding region 
predicted to result in a truncated protein 
and 2 independent occurrences of a non-
coding variant (var321) in the binding site for 
microRNA (miRNA) hsa-miR-189 were identified 
in TS probands but not in over 3600 controls. 
The patient having the frameshift mutation 
was diagnosed with ADHD in addition to TS 
and the patient’s mother who had the same 
mutation was affected with trichotillomania 
(compulsive hair pulling) (TTM) but not TS. 
The individuals carrying var321 however had 
OCD-like symptoms in addition to TS and a 
family history of tics, OCD-like symptoms and/
or hair pulling. OCD, ADHD and/or TS might 
represent alternative manifestations of a single 
underlying genetic alteration. SLITRK1 mRNA 
and miR-189 have an overlapping expression 
pattern in the developing brain and in vitro 
reporter gene activity is reduced through 
action of miR-189, with further repression 
occurring in the presence of the var321. 
miRNAs are post-transcriptional RNA regulators 
that bind to complementary sequences on 
target mRNAs to halt their translation. SLITRK1 
was found to regulate neurite outgrowth, a 
process that is inhibited in the absence of 
SLITRK1 phosphorylation [38] and the presence 
of the frameshift mutation [2]. Furthermore, 
14-3-3 proteins, which are involved in a 
multitude of cellular processes, ranging from 
proliferation and differentiation to membrane 
excitability, were found to interact with SLITRK1 
[38]. Several follow-up studies that screened 
for the observed SLITRK1 genetic changes in 
TS either failed to find them [39-42], or when 
identified, they did not segregate with the 
disorder in families [43,44], hence clouding the 
link between SLITRK1 and TS. In this context, the 
original authors rejected claims of confounding 
population stratification between cases and 
controls [45], and recent studies by us and other 
groups have re-highlighted the significance of 
the initial findings by demonstrating a strong 
over-transmission of alleles and/or haplotypes 
of SLITRK1 to affected individuals [46-48].
The discovery of HDC as a TS susceptibility 
locus shifted a massive knowledge set on 
histamine biosynthesis and histaminergic 
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neurotransmission, painstaking gathered in the 
last two decades, in the direction of TS. Through 
the analysis of linkage in a two-generation 
pedigree, in which TS segregated in a rare 
autosomal dominant manner, Ercan-Sencicek 
et al. [1] identified a rare functional mutation 
(W317X) in the HDC gene. The W317X nonsense 
mutation, which is present in a heterozygous 
form in the affected offspring and affected 
father but not in the unaffected mother and in 
more than 3000 controls, is predicted to result 
in a truncated protein that lacks key parts of 
the enzyme’s active domain. Although the 
truncating mutation could potentially result in 
haploinsufficiency (that leads to low histamine 
levels in the central nervous system), the authors 
showed convincingly that the retained mutant 
protein lacked enzymatic activity and had a 
dominant-negative effect on the function of 
the wild-type protein. Furthermore, the study 
established that loss-of-function HDC alleles are 
extremely rare and in this context, the first follow-
up study reported no significant association 
between the HDC gene and TS in a cohort of 120 
Chinese Han patients [49]. The major active form 
of the histamine-synthesising HDC enzyme is a 
homodimer and uses pyridoxal 5’-phosphate as 
a cofactor. Following conversion from histidine, 
histamine is stored in synaptic vesicles via the 
vesicular monoamine transporter-2 (VMAT-
2) ready to be released at the synaptic cleft 
by exocytosis. The effects of histamine in the 
CNS are achieved through 3 types of guanine 
nucleotide (G) protein-coupled receptors. H1 
and H2 receptors are located postsynaptically 
and are mostly the mediators of the excitatory 
actions of histamine. The H3 receptors act as 
somatodendritic autoreceptors that inhibit 
firing of neurons or as presynaptic receptors 
that inhibit the release of histamine and 
other neurotransmitters from axon terminals 
[reviewed in 50]. 
All in all, there is a consensus that the TS 
gene discovery story has had a promising start. 
Although mutations in the genes discovered 
are found in only a small fraction of affected 
persons, there is presently an impetus to delve 
into protein function as well as the mechanisms 
through which loss of function leads to TS. 
In this regard, the next stop of the journey 
towards the clinic is definitely animal models.
MOUSE MODELS OF TS: TICKLISH 
QUESTIONS
What makes a valuable animal model of 
human disease? Considering, for instance, 
the paediatric neurological disease spinal 
muscular atrophy (SMA) [51-53], we note that 
the underlying neurodegenerative pathology 
can be fully reproduced in an animal because: 
firstly, the aetiology, which involves a deficiency 
of the survival of motor neurons (SMN) protein, 
is clearly defined [54]; secondly, the disease 
manifestations in mice are noticeable and 
quantifiable including decreased lifespan, 
motor neuron loss, atrophic muscle fibres as 
well as motor defects [55-58]; and, thirdly, such 
abnormalities can be relieved by therapies 
known to be effective in humans such as 
those that increase SMN levels [59-62]. From a 
neuroanatomical viewpoint, there is increasing 
evidence pointing towards the cortico-striato-
thalamo-cortical (CSTC) pathways as the site 
of origin of tics as well as the accompanying 
neuropsychiatric problems. However, because 
the precise cellular and molecular mechanisms 
of the underlying abnormalities in TS are still 
hazy, animal models of TS have been hard 
to come by. The recent successes in TS gene 
discovery were thought to pave the way for 
genetic models that closely replicate the TS 
phenotype.
In the era preceding TS gene discovery, 
the animal model that by far exhibited the 
greatest behavioural similarities to TS is the 
D1 receptor cholera toxin (D1CT-7) transgenic 
mouse [63,64]. This model has cortical-
limbic hyperactivity triggered through the 
expression of a transgene constructed by 
fusing the promoter region for the human 
D1 dopamine receptor with the intracellular 
A1 subunit of the cholera toxin. In addition to 
OCD-like behaviours that include generalised 
behavioural perseveration, repetitive leaping 
and compulsion-like grooming-associated 
pulling and biting of skin and hair [63], D1CT-7 
mice spontaneously display TS-like behaviours 
such as tics and ‘twitch’ flurries of the head, 
limbs and trunk that have a juvenile-onset [64]. 
Notably, tics were reduced following treatment 
with clonidine, an a2-adrenergic agonist that 
is frequently used to treat patients with TS. In 
this context, knockout of Slitrk1 or Hdc was 
predicted to result in a mouse model that 
resembled the D1CT-7 mice, which due to their 
striking similarity to human tic behaviours were 
thought to have good predictive validity in 
developing therapeutic drugs for the treatment 
of tics.
Slitrk1-knockout mice, which are totally 
deficient or null for Slitrk1, did not exhibit any 
external abnormalities though viability was 
slightly decreased and males had a reduced 
body weight. In the elevated plus-maze test, 
which involves placing a mouse in a plus-
shaped apparatus with two open and two 
enclosed arms, elevated from the floor, Slitrk1-
deficient mice exhibited a reduction in the 
number of entries into open arms as well as 
time spent in open arms, with such phenotypes 
pointing towards an elevated anxiety-like 
behaviour. An increased immobility time in 
the tail suspension and forced swimming 
tests was also noted, with the latter indicating 
that Slitrk1-knockouts exhibit depression-
like behaviour. Brains of mutant mice had an 
elevated level of noradrenaline as well as its 
metabolite 3-methoxy-4-hydroxyphenylglycol 
(MHPG) and administration of clonidine 
attenuated the anxiety-like behaviour of the 
knockout animals [3]. Although anxiety and 
depression are at times part of the clinical 
repertoire of TS [65,66], Slitrk1-null mice had 
no compulsive and/or tic-related behaviours, 
a result that was unexpected given that in 
addition to TS, SLITRK1 has also been linked to 
TTM [2,67], which like TS is believed to belong 
to the OCD spectrum.
Hdc-knockout mice are not able to produce 
histamine and, hence, lack histamine-dependent 
activation through histamine receptors. Hdc-/- 
mice are viable, fertile and healthy but display 
altered mast cell morphology and low mast cell 
numbers [68]. Generated well before HDC was 
linked to TS, these knockout mice have been 
utilised to investigate the role of histamine 
in immunity, wound healing, cardiovascular 
function, parasitic infections, inflammation, 
gastric acid secretion and allergic disorders 
[reviewed in 69,70]. To uncover the function 
of Hdc in neurophysiology, several studies 
subjected Hdc-deficient mice to an array of 
behavioural assays. Mutant animals have 
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reduced spontaneous locomotor activity in the 
dark and exhibit a decreased exploratory activity 
in an illuminated open-field [4,5]. However, 
repeated administration of methamphetamine 
(METH) induced marked hyperactivity and 
behavioural sensitisation in knockout mice 
compared to their wild-type counterparts [4]. 
By inhibiting the reuptake and facilitating the 
release of dopamine, repeated treatment with 
METH induces behavioural sensitisation in 
mice, which involves a progressive and long-
lasting elevated locomotor activity as well as 
stereotyped behaviour or behaviour that is 
both repetitive and excessive in nature. Hdc-
knockouts had heightened measures of anxiety 
in the elevated plus-maze test which might 
explain their hypoactivity [5,6]. Although such an 
observation is similar to Slitrk1-deficient mice [3], 
Hdc-null brains had low levels of noradrenaline 
[4]. Hdc-/- mice display traits that resemble 
features of TS including anxiety and dopamine 
agonist-triggered stereotypic movements, 
however, the murine phenotype certainly never 
reaches the levels of TS resemblance seen for 
instance in the D1CT-7 transgenic mouse.
Considering their poor resemblance to 
the human condition, it is certainly clear that 
both the Slitrk1 and Hdc mouse knockouts 
are not good models of TS (Figure 1). How 
can we overcome the existing hurdles in the 
development of a genetic model of TS? A key 
approach should involve a rethink of model 
design. It is highly probable that patients 
with SLITRK1 mutations have an altered 
SLITRK1 expression and not a total knockout 
as happens in Slitrk1-/- mice. Indeed, SLITRK1 
was originally implicated in TS because 
it neighboured a chromosomal inversion 
that was hypothesised to influence SLITRK1 
expression pattern and levels [2]. Furthermore, 
the proximity of SLITRK5 (13q31.2) and SLITRK6 
(13q31.1) to the SLITRK1 gene (13q31.1) means 
that these two SLITRK family members (and, 
possibly, other nearby genes) could also be 
influenced by a position effect. The recent 
finding of OCD-like behaviours manifesting as 
excessive self-grooming in the Slitrk5 mouse 
knockout seems to point in this direction 
[71]. In contrast to the Slitrk1-/- mouse, the 
genetic lesion in Hdc-/- mice is probably quite 
similar to that described in patients with TS 
that have HDC mutations. Indeed, Hdc-/- mice 
have a targeting vector that entirely replaces 
exons 6-8 of the murine 12 exon-long Hdc 
gene. Hence, similar to patients with TS who 
carry the W317X nonsense mutation [1], a 
truncated Hdc protein lacking the pyridoxal 
5’-phosphate (PLP) domain and probably 
acting in a dominant-negative way could be 
produced in HdcD6-8 mice. To our knowledge, 
Western blotting experiments as well as 
studies that assess the effect of the truncated 
Hdc protein on its wild-type counterpart still 
Figure 1.  Genetic alterations in SLITRK1 and HDC genes in patients with TS and present genetic mouse models. (A) A schematic of the SLITRK1 gene (green = translated; red = 
untranslated regions) with the reported alterations in TS (white strips) and its translated product. SLITRK1 protein has several conserved protein domains including 
leucine-rich repeats (LRR), a leucine-rich repeat C-terminal domain (LRRCT), a leucine-rich repeat N-terminal domain (LRRNT) and a transmembrane domain (TM). 
Patients with TS that have genetic alterations in the SLITRK1 gene are hypothesised to have either altered expression (var321) or expression of a truncated version 
(L422fs) of SLITRK1. Mice have a total knockout of the Slitrk1 gene and exhibit anxiety and depression but no spontaneous tics. (B) A schematic of the HDC gene 
(green = translated; red = untranslated regions) with the reported alterations in TS (white strips) and its translated product. HDC protein has several conserved 
protein domains including the pyridoxal 5’-phosphate (PLP) domain at the N-terminal end, two proline, glutamic acid, serine and threonine-rich PEST domains 
(PEST1 and PEST2) and a C-terminal intracellular targeting domain (ER2). Patients with TS that have genetic alterations (W317X) in the HDC gene are thought to 
express a truncated version of HDC lacking a part of the PLP domain, the PEST2 domain and the ER2 domain. In Hdc-/- mice, the targeting vector replaces exons 
6-8 (and part of exon9) and a truncated protein similar to the one described in patients could be produced. Mice exhibit anxiety and tics that are not spontaneous 
but dopamine agonist-induced. Alteration of the PLP domain has a negative impact on the binding of pyridoxal 5’-phosphate, an essential coenzyme for HDC 
activity. aa - amino acids. 
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need to be done to prove these hypotheses. 
The absence of TS-like behaviours in mice 
with a genetic lesion which is similar to that 
described in patients with TS would certainly 
raise questions about the causative link 
between HDC and TS.
CONCLUSIONS
If SLITRK1 and HDC are indeed linked to TS, 
genetic alterations of the respective gene locus 
most probably account for an extremely small 
fraction of TS cases. Nonetheless, the discovery 
of these rare genetic lesions have spurred 
research efforts aimed at the identification of 
the pathophysiological mechanisms underlying 
TS including development of genetic animal 
models. However, the incomplete phenotypic 
penetrance in the existing genetic models of TS 
renders them unsuitable for use in translational 
medicine. In this regard, establishing a 
genetic animal model that faithfully mimics 
the hallmark features of TS remains a major 
stumbling block in deciphering the molecular 
basis of this disorder as well as the discovery 
of novel drugs that alleviate the phenotypic 
spectrum of affected patients. Ways forward 
should involve the construction of mice models, 
which have a genetic aberration that closely 
mimics the one found in patients and the use of 
alternative animal models. In this respect, the 
fruit fly Drosophila melanogaster is an excellent 
choice in view of its role in deciphering the 
genetic basis of behaviour and the successes 
in modelling various neurological disorders 
including neuropsychiatric conditions such 
as schizophrenia, bipolar disorder and autism 
[72-75]. The road from lab to clinic is 
unquestionably long and winding but 
nevertheless filled with exciting opportunities.  
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